What is the current stock price of Biotricity, Inc. (BTCY)?

As of the latest market data, Biotricity, Inc. (BTCY) is trading at $0.25. The stock has seen a loss of -5.31% today.

Does Biotricity, Inc. (BTCY) pay a dividend?

Based on current data, Biotricity, Inc. does not have a confirmed active dividend policy.

What is the market cap of Biotricity, Inc.?

The current market capitalization of Biotricity, Inc. (BTCY) is approximately unavailable.

BTCY

Biotricity, Inc.·Healthcare

0.25

5.310%(−0.01)

Market Closed

0.29

18.271%(+0.04)

After Hours

Last Updated: — ET

52W L: $0.2052W H: $0.75

BTCY NEWS

defenseworld.net

Feb 20

Financial Survey: 10x Genomics (NASDAQ:TXG) and Biotricity (OTCMKTS:BTCY)

Biotricity (OTCMKTS:BTCY - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Biotricity and 10x

seekingalpha.com

Feb 11

Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript

globenewswire.com

Feb 11

Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.

globenewswire.com

Feb 5

Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time.

defenseworld.net

Jan 12

Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)

Biotricity (OTCMKTS:BTCY - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings

Company Profile

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2018-02-16

Beta

1.40

Websitewww.biotricity.com↗